Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $125.00 at HC Wainwright

Vera Therapeutics (NASDAQ:VERA) had its target price lifted by stock analysts at HC Wainwright from $110.00 to $125.00 in a report released on Wednesday, MarketBeat.com reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 190.97% from the stock’s previous close.

VERA has been the subject of several other research reports. Bank of America boosted their price objective on Vera Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday. Evercore set a $91.00 target price on shares of Vera Therapeutics in a research report on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target on the stock in a research report on Wednesday, March 11th. Finally, Jefferies Financial Group restated a “buy” rating and set a $60.00 price target on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $79.90.

Vera Therapeutics Trading Up 7.1%

NASDAQ:VERA opened at $42.96 on Wednesday. Vera Therapeutics has a 12 month low of $19.07 and a 12 month high of $56.05. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. The firm’s 50 day moving average is $36.29 and its 200 day moving average is $41.20. The stock has a market capitalization of $3.08 billion, a PE ratio of -7.75 and a beta of 0.92.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period last year, the firm earned ($0.81) earnings per share. Sell-side analysts expect that Vera Therapeutics will post -6.23 earnings per share for the current year.

Insider Transactions at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 22,951 shares of the stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $44.05, for a total value of $1,010,991.55. Following the transaction, the chief executive officer owned 235,244 shares of the company’s stock, valued at $10,362,498.20. This represents a 8.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 59,951 shares of company stock valued at $2,392,387 in the last ninety days. 15.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Vera Therapeutics

Several institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its position in Vera Therapeutics by 49.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock worth $276,595,000 after purchasing an additional 1,795,537 shares during the period. Vestal Point Capital LP boosted its position in Vera Therapeutics by 24.0% during the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after buying an additional 600,000 shares during the period. Integral Health Asset Management LLC boosted its position in Vera Therapeutics by 47.8% during the third quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock valued at $49,402,000 after buying an additional 550,000 shares during the period. Elmind Capital LP bought a new position in shares of Vera Therapeutics during the fourth quarter valued at about $24,434,000. Finally, Braidwell LP bought a new position in shares of Vera Therapeutics during the third quarter valued at about $13,738,000. 99.21% of the stock is currently owned by institutional investors.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.